Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 6/20 | 0.34 |
| ▸ | ATR | Q13535 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12743544 | 1.00 | MAP3K14 (0.46) | MAP3K14CNR2ERBB2KDREPHA2 | |
| SCHEMBL12743908 | 0.95 | MAP3K14 (0.50) | MAP3K14CNR2MAP4K4KCNH2PRKDC | |
| SCHEMBL1614897 | 0.86 | MAP3K14 (0.64) | MAP3K14MAP4K4 | |
| SCHEMBL1822232 | 0.86 | MAP3K14 (0.64) | MAP3K14MAP4K4 | |
| SCHEMBL1614900 | 0.86 | MAP3K14 (0.64) | MAP3K14MAP4K4 | |
| SCHEMBL12743891 | 0.85 | MAP3K14 (0.43) | MAP3K14CNR2MAP4K4 | |
| SCHEMBL12743918 | 0.85 | MAP3K14 (0.43) | MAP3K14CNR2MAP4K4 | |
| SCHEMBL12743240 | 0.83 | MAP3K14 (0.52) | MAP3K14KDRKCNH2PRKDCEGFR | |
| SCHEMBL12743916 | 0.83 | ERBB2 (0.35) | MAP3K14CNR2ERBB2KDREPHA2 | |
| SCHEMBL12742573 | 0.81 | MAP3K14 (0.45) | MAP3K14CNR2KCNH2PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | MAP3K14 17/4885CNR2 1549/4885ERBB2 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.